Experienced in Pancreatic Islet Cell Tumor

Chris Verslype

Leuven, VLG, BE 
Experienced in Pancreatic Islet Cell Tumor
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Chris Verslype practices in Leuven, Belgium. Mr. Verslype is rated as an Experienced expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Neuroendocrine Tumor, Liver Cancer, Cerebral Hypoxia, Liver Transplant, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Male

Locations

Leuven, VLG, Belgium
Other Locations
Cliniques Universitaires Saint Luc
Brussels, BRU, Belgium
UZ Gent
Gent, VLG, Belgium
AZ Groeninge
Kortrijk, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial
Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial
Enrollment Status: Terminated
Publish Date: January 27, 2021
Intervention Type: Radiation, Device
Study Phase: Phase 2
View 1 Less Clinical Trial

198 Total Publications

Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma.
Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma.
Journal: Gut pathogens
Published: June 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Verslype's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile